Study of Oral Navitoclax Tablet in Combination With Oral Ruxolitinib Tablet Versus Best Available Therapy to Assess Change in Spleen Volume in Adult Participants With Relapsed/Refractory Myelofibrosis
A phase 3 trial testing Navitoclax in myeloproliferative neoplasms, active and no longer recruiting.
Overview
Study of Oral Navitoclax Tablet in Combination With Oral Ruxolitinib Tablet Versus Best Available Therapy to Assess Change in Spleen Volume in Adult Participants With Relapsed/Refractory Myelofibrosis is a phase 3 interventional study registered as NCT04468984, led by AbbVie, and active but no longer recruiting when checked on 2026-09-11. Official title: Randomised, Open-Label, Phase 3 Study Evaluating Efficacy and Safety of Navitoclax in Combination With Ruxolitinib Versus Best Available Therapy in Subjects With Relapsed/Refractory Myelofibrosis (TRANSFORM-2), Incorporating Extension Arm C - Continued Access for Navitoclax to Roll Over Subjects From Studies M10-166, M16-109, M16-191, and M19-753. Planned enrolment is 330 participants (estimated). The study started in 2020-08-31 and primary completion is expected in 2025-01-29. No results have been posted on ClinicalTrials.gov.
Similar pages
not linked directly; found by shared links- TrialA Study Assessing Adverse Events and Disease Activity of Intravenously (IV) Infused Telisotuzumab Adizutecan in Adult Participants With c-Met Protein Above Cutoff Level Above Refractory Metastatic Colorectal Cancer
Shares AbbVie (incl. ImmunoGen, Capstan) and the tag ctgov-ingest.
- TrialA Study to Assess Adverse Events, Change in Disease Activity of Intravenous Telisotuzumab Adizutecan in Combination With Osimertinib as First-Line Treatment in Adult Participants With Locally Advanced Unresectable or Metastatic EGFR-Mutated Non-Squamous Non-Small Cell Lung Cancer
Shares AbbVie (incl. ImmunoGen, Capstan) and the tag ctgov-ingest.
- TrialA Study to Assess Adverse Events and Change in Disease Activity of Intravenous (IV) Telisotuzumab Adizutecan, Monotherapy or in Combination With Osimertinib, Compared to Standard of Care in Adult Participants With Locally Advanced or Metastatic EGFR-Mutated Non-Squamous Non-Small Cell Lung Cancer
Shares AbbVie (incl. ImmunoGen, Capstan) and the tag ctgov-ingest.
- TrialA Study to Access Intravenous (IV) Telisotuzumab Adizutecan in Combination With IV Bevacizumab Compared to Standard of Care IV Bevacizumabin Combination With Oral Trifluridine and Tipiracil in Adult Participants With Refractory Metastatic Colorectal Cancer
Shares AbbVie (incl. ImmunoGen, Capstan) and the tag ctgov-ingest.
- TrialA Study to Evaluate Adverse Events and Change in Disease Activity of Intravenous ABBV-706 Versus Standard of Care in Adult Participants With Relapsed/Refractory Small Cell Lung Cancer
Shares AbbVie (incl. ImmunoGen, Capstan) and the tag ctgov-ingest.
- TrialA Study to Evaluate Safety and Efficacy of Bomedemstat (MK-3543-017)
Shares Myeloproliferative neoplasms (PV, ET, myelofibrosis) and the tag ctgov-ingest.
- TrialStudy to Evaluate Adverse Events, Optimal Dose, and Change in Disease Activity, With Livmoniplimab in Combination With Budigalimab Plus Chemotherapy Versus IV Infused Pembrolizumab Plus Chemotherapy in Adult Participants With Untreated Metastatic Non-Squamous Non-Small Cell Lung Cancer (NSCLC)
Shares AbbVie (incl. ImmunoGen, Capstan) and the tag ctgov-ingest.
- TrialA Study to Assess the Dose, Adverse Events, and Change in Disease Activity of Livmoniplimab as an Intravenous (IV) Solution in Combination With Budigalimab as an IV Solution in Adult Participants With Hepatocellular Carcinoma (HCC)
Shares AbbVie (incl. ImmunoGen, Capstan) and the tag ctgov-ingest.